Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting

被引：5
|
作者：
Hobbs, Miriam [1 ]
Paludo, Jonas [1 ]
Fonder, Amie [1 ]
Abeykoon, Jithma P. [2 ]
Gertz, Morie A. [1 ]
Rajkumar, S. Vincent [1 ]
Go, Ronald S. [1 ]
Buadi, Francis K. [1 ]
Lacy, Martha Q. [1 ]
Leung, Nelson [1 ]
Dispenzieri, Angela [1 ]
Gonsalves, Wilson I. [1 ]
Dingli, David [1 ]
Hwa, Yi L. [1 ]
Kourelis, Taxiarchis [1 ]
Kyle, Robert A. [1 ]
Kumar, Shaji [1 ]
Kapoor, Prashant [1 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Mayo Clin, Dept Internal Med, Rochester, MN USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.3337.3337
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3337
引用
收藏
页数：6
相关论文
共 50 条
  • [11] Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)
    Chen, Christine I.
    Bahlis, Nizar J.
    Gasparetto, Cristina
    Tuchman, Sascha A.
    Lipe, Brea
    Baljevic, Muhamed
    Kotb, Rami
    Sutherland, Heather J.
    Bensinger, William I.
    Sebag, Michael
    LeBlanc, Richard
    Venner, Christopher P.
    Schiller, Gary J.
    Lentzsch, Suzanne
    Callander, Natalie S.
    Rossi, Adriana C.
    Sheehan, Heidi
    Van Domelen, Dane
    Kazuharu, Kai
    Wang, Hongwei
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    White, Darrell J.
    BLOOD, 2020, 136
  • [12] Real World Analysis of the Efficacy, Prognosis and Safety of Daratumumab, Carfilzomib, and Dexamethasone (DKD) in Relapsed or Refractory Multiple Myeloma Patients
    Fu, Chengcheng
    You, Hongying
    Jin, Song
    Wang, Panfeng
    Yan, Lingzhi
    Zhang, Liying
    Lu, Tingting
    Gao, Xiao
    Jiang, Lei
    Qiu, Hongchun
    Shang, Jingjing
    Zhai, Yingying
    Yao, Weiqin
    Yan, Shuang
    Yan, Zhi
    Wu, Depei
    BLOOD, 2024, 144 : 6992 - 6993
  • [13] Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States
    Pelligra, Christopher G.
    Parikh, Kejal
    Guo, Shien
    Chandler, Conor
    Mouro, Jorge
    Abouzaid, Safiya
    Ailawadhi, Sikander
    CLINICAL THERAPEUTICS, 2017, 39 (10) : 1986 - 2005
  • [14] Real-World Safety and Early Efficacy of Talquetamab in Patients with Heavily-Pretreated Relapsed/Refractory Multiple Myeloma
    Costa, Bruno
    Tan, Carlyn
    Shekarkhand, Tala
    Firestone, Ross
    Jurgens, Eric
    Miller, Kevin
    Lesokhin, Alexander
    Shah, Gunjan
    Korde, Neha
    Rajeeve, Sridevi
    Chung, David
    Landau, Heather
    Scordo, Michael
    Hassoun, Hani
    Maclachlan, Kylee
    Shah, Urvi
    Hultcrantz, Malin
    Hamadeh, Issam
    Giralt, Sergio
    Mailankody, Sham
    Usmani, Saad
    Hashmi, Hamza
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S46 - S47
  • [15] Real-World Safety and Early Efficacy of Talquetamab in Patients with Heavily-Pretreated Relapsed/Refractory Multiple Myeloma
    Costa, Bruno Almeida
    Tan, Carlyn Rose
    Shekarkhand, Tala
    Firestone, Ross S.
    Jurgens, Eric M.
    Miller, Kevin
    Lesokhin, Alexander M.
    Shah, Gunjan L.
    Korde, Neha
    Rajeeve, Sridevi
    Chung, David J.
    Landau, Heather J.
    Scordo, Michael
    Hassoun, Hani
    Maclachlan, Kylee H.
    Shah, Urvi A.
    Hultcrantz, Malin
    Hamadeh, Issam S.
    Giralt, Sergio
    Mailankody, Sham
    Usmani, Saad Z.
    Hashmi, Hamza
    BLOOD, 2024, 144 : 7026 - 7027
  • [16] REAL-WORLD EXPERIENCE OF LENALIDOMIDE/DEXAMETHASONE TREATMENT FOR REFRACTORY/RELAPSED MULTIPLE MYELOMA (RRMM) PATIENTS
    Tognazzi, L.
    Rivolti, E.
    Quaresima, M.
    Labbozzetta, S.
    Gamberi, B.
    Merli, F.
    HAEMATOLOGICA, 2017, 102 : 137 - 137
  • [17] Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting
    Kumar, Shaji K.
    Fu, Alan
    Mezzi, Khalid
    Braunlin, Megan
    Kim, Christopher
    Iskander, Karim
    Niesvizky, Ruben
    Jagannath, Sundar
    Boccia, Ralph
    Raje, Noopur
    BLOOD, 2018, 132
  • [18] A SINGLE CENTER EXPERIENCE OF POMALIDOMIDE PLUS DEXAMETHASONE (PD) IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)
    Duran, M.
    Tombuloglu, M.
    Tobu, M.
    Vural, F.
    Sahin, F.
    Patir, P.
    Uysal, A.
    Saydam, G.
    LEUKEMIA RESEARCH, 2016, 49 : S18 - S19
  • [19] Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data
    Sandecka, Viera
    Pour, Ludek
    Spicka, Ivan
    Minarik, Jiri
    Radocha, Jakub
    Jelinek, Tomas
    Pavlicek, Petr
    Jungova, Alexandra
    Kessler, Petr
    Wrobel, Marek
    Stork, Martin
    Straub, Jan
    Pika, Tomas
    Capkova, Lenka
    Sevcikova, Sabina
    Maisnar, Vladimir
    Hajek, Roman
    NEOPLASMA, 2022, 69 (06) : 1474 - 1479
  • [20] Carfilzomib Prescribing Patterns and Outcomes for Relapsed or Refractory Multiple Myeloma (RRMM): A Real-World Analysis
    Dong, Sharlene
    Banerjee, Rahul
    Khan, Adeel
    Wang, Mengru
    Wang, Xiaoliang
    Afghahi, Anosheh
    Afrough, Aimaz
    Janakiram, Murali
    Wang, Bo
    Cowan, Andrew
    Sperling, Adam
    Anderson, Larry
    Rajkumar, S. Vincent
    Kaur, Gurbakhash
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S258 - S259
12345